التفاصيل البيبلوغرافية
| العنوان: |
Uso de gammaglobulina en el trasplante de células progenitoras hematopoyéticas y trasplante renal. (Spanish) |
| المؤلفون: |
Alberto Ruíz-Morales, Jorge, Shanat Cruz-Medina, Cinthya, Pérez-García, Martín, Campos-Gutiérrez, Ma. de los Ángeles, del Campo-Martínez, Mariana, Olaya-Vargas, Alberto |
| المصدر: |
Acta Pediatrica de Mexico; nov/dic2013, Vol. 34 Issue 6, p348-352, 5p, 2 Diagrams |
| مصطلحات موضوعية: |
KIDNEY transplantation, PROGENITOR cells, IMMUNOLOGICAL deficiency syndromes, IMMUNOGLOBULIN G, IMMUNOTHERAPY, GRAFT rejection, HEMATOPOIETIC stem cell transplantation, AUTOIMMUNE diseases |
| Abstract (English): |
Intravenous immunoglobulin (IVIG) preparation comprise a pooled IgG antiboidies from the serum of thousands of donors and has been used as therapy in several pathologies such as: primary immunodeficiency's, autoimmune diseases, Kawasaki disease and on transplantation field to treat graft versus host disease, viral infections and sensitization due to anti-donor antibodies. The anti-donor antibodies are an important risk factor for acute humoral rejections on kidney transplantation and are a very important risk factor for graft failure after hematopoietic stem cell transplantation. Using IVIG to treat patients with anti-donor antibodies might reduced the risk of acute kidney rejection and graft failure following hematopoietic stem cell transplantation [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): |
La gammaglobulia intravenosa (GGIV) contiene un concentrado de anticuerpos IgG obtenidos de miles de donadores y se ha utilizado como terapia en varias enfermedades, como: inmunodeficiencias primarias, enfermedades autoinmunitarias y enfermedad de Kawasaki. En el área de trasplante se ha usado la GGIV en el tratamiento de infecciones virales, enfermedad injerto contra huésped y en la sensibilización por anticuerpos antidonador. Estos últimos son un factor de riesgo importante para el rechazo agudo mediado por anticuerpos en el trasplante renal y para la falla de injerto durante el trasplante de células progenitoras hematopoyéticas. El uso de GGIV como tratamiento para la sensibilización de los pacientes que se someterán a trasplante renal o de progenitores hematopoyéticos reduce el riesgo de rechazo agudo del injerto. [ABSTRACT FROM AUTHOR] |
|
Copyright of Acta Pediatrica de Mexico is the property of Instituto Nacional de Pediatria (INP) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder